Taysha Gene Therapies (TSHA) PT Raised to $13 at Goldman Sachs
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Price: $5.02 -2.71%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $13.00 (from $11.00) while maintaining a Buy rating.
You May Also Be Interested In
- Wolfe Research Starts Taysha Gene Therapies (TSHA) at Outperform
- JPMorgan Downgrades Mapletree Logistics Trust (MLT:SP) (MAPGF) to Neutral
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
